INmune Bio (INMB) 2 Nov 222022 Q3 Earnings call transcript

Greetings, and welcome to the INmune Bio Third Quarter 2022 Earnings Call. [Operator Instructions].

At this time, it is my pleasure to introduce Mr. David Moss, CFO of INmune Bio. David, thank you. yours. now is floor The

call Lowdell, Thank of on of dominant you, for Bio's We or you Dr. on DN-TNF afternoon, Quarter platform, of Tesi, Bio, INmune will Bio; a the is who provide on and us for together good and call the me joining TNF With INmune an Barnum, provide Officer oncology Financial everybody. business natural INKmune, Dr. negative the update Chief Dr. RJ XXXX will who CEO Head thank CJ our Results. Mark Donna, is Neuroscience, short. INmune call Third killer on Also Scientific platform. our update for cell memory-like for

statements Before responses we Private Act statements of and of These management made Securities questions the to under that provision statements Reform can involve begin, call and by statements the I facts, remind are for the this Litigation except historical conference on harbor’s forward-looking uncertainties XXXX. safe everyone of risks that results SEC recent differ the of as disclaimers statements. statements There's those see from earnings Please our to including specific the any materially in with no forward-looking forward-looking the in company's release factors outcome. such as the risk company's press quarterly well filing filings, most on assurance actual SEC. cause

underlying to to facts circumstances events speak any of the required disclaims these future as and only date update as law, forward-looking should reliance circumstances. which change. INmune made on be Bio forward-looking not as are statements, Undue statements or information, by statements obligation Except the forward-looking placed they reflect may these

turn Bio. now over us, behind Tesi, Dr. call statements the RJ? CEO to of forward-looking I'd like RJ the to INmune With

call today's bit organized And differently. David. little you, a Thank is

-- on, we people I forward, believe those hear have investors We that are the believe programs because going learn company for the lot And calls will from C.J. this they larger the and most Mark on responsible you cast the are with going a we a of when see Lowdell and call. programs. Barnum complicated on both that directly

begin are top obviously, So with the we issue the hold. that under will I with comments. some is from line the most -- FDA. And expo clinical important just

previously, manufacturing manufacturing was are placed and controls related on by are release batches some testing. As problems technical separated clinical issues. and to nature, to they the plants, These stated has were this manufacturing we the by manufacturing due and caused hold in that fact XProXXXX many i.e., the and related different geography, years to issues

manufacturing hurdles. with progress we And the Australia. working and in ADXX hopefully coiled will patients to to hold and XPro the mild impairment, continue or have closely with this that exploring problems, both in will and forward to in be work the teams a Once venues program look in Alzheimer's jurisdictions. all lifted, trial been we we trial AD spring. ADXX We is and disease Despite these like clearing patients FDA mild have and continue enroll The clinical are to other able very delay, these enroll continue our regulatory to or is to we regulatory the we resolve cognitive patients. to to make ADXX open enrolling mild MCI begin

Soon program depression we those the the enrolling, in after programs treatment-resistant X launch to plan are U.S.

the on Alzheimer's FDA. the trials guidance in Obviously, readouts the discussions the of with on readouts those timing of timing end the Importantly, we the depends top our at will line year. update of

it pass CJ back Barnum, programs. will to Neurosciences, of the I Alzheimer's to Phase II Dr. VP speak the now about

Thank you, RJ.

is randomized, XPro treated ADXX cognition X for ADXX in for to study. continue placebo-controlled with we study patients As patients Australia enroll the RJ months. in evaluating a blinded, mentioned,

Notably, has elected and efficacy this patient first open-label safety a XPro. the that to where in announce extension study an received patients study. are II enroll to open-label in the extension enroll is open-label study. pleased study patient XX-month This the has extension Phase evaluated are We unblinded in completed that our All X-month fashion.

extension The purposes. has X open-label

are a First, the participation a year is in recruiting offered it tool. of after Patients therapy trial.

Second, this our safety and approval. other in provides and approval on strategy. focus The helps FDA required safety. extension the both The for expanded regulatory efficacy and product extended authorities open-label database

months. I the MRI Finally, efficacy long-term improvement through Phase extension continuous in the showed trial, open-label data provides biomarkers XX

from data do placebo-controlled nor inform the they clinical the are information blinded, not will While open-label that provide additional strategy. extension the development

open-label expect in extension the XXXX. report We data to from

that reinforce this ever confident for X as drug the right remain right we target. Finally, belief. we have the developments as recent

first literature for evidence from targeting continues the comes TNF. provide that The to

has study risk risk studies of TNF AD of records Yet and/or are epidemiological now dementia. than the the XX reduce anti-TNF There that reported million by show nationwide another more examining inhibitors therapies that XX%. up to X reduce dementia

I study. The treated second Phase the patients from comes in

therapy. extremely to on been have by their desire encouraged remain We

of access we result opened a program persistence, As United in a in special use compassionate like their Australia, States. have the

access avenue information. Australia, patients a long-term to have As now and to of we safety in result, collecting have expo get another another means

to back I'd like the pass to call R.J. Now

I for on Thank you, the focused INKmune, The is is only U.K. progress. clinical This cell tumors. XX% to MDS/AML of trial landscape liquid program. therapies priming oncology mainly CJ. our The I'll program killer now natural to continues cancers. program move cell Phase in

need in is We by preclinical is not meets or of potential. even an served of an cell INKmune for solid unmet be historically have We treatment tumors. therapy data not even Historically with generated the solid -- that group of cancers INKmune that currently, may solid great tumors medical ideal compelling that tumors are solid XX% tumors suggest this therapies. human towards believe refocusing cancers well

describe Dr. pass of in Scientific Mark to more detail. to I'll Chief Mark? this it Lowdell, Officer INmune Bio the

thank and joining everyone, RJ, call. today's you, for Thank you,

release we just cell in solid our with only XX% the weeks RJ So on liquid tumors, community solid of as our lines of cancers cancer are with in cell the as efficacy cancers as recent are ago, the tumor RJ we that majority a data on or press human couple topic, of focused shared And tumors. investment just said, to. hematologic therapies the highlighted INKmune cancers positive and licensed multiple recent alluded currently

The the or within recent the and cells had for insights some for into or build we've believes active data NK obtained calls TME the field on why years we've data short. and natural tumor override company hypoxia provide cells killer INKmune and cells microenvironment that what to regulatory immunosuppressive the nature the

cancer interaction be progression. are all the of the the moment. why So or resident the cells with And many reason setting maybe therapies tumor with in infiltrating that most immune still cells to ineffective cell drives and the TME at it's

tumors solid what a complex of TMEs presence we levels to of these interactions hypoxia. because of cell the regulatory cells; immunosuppressive hostile have call So one, oxygen. considered therapies to when the designing low and That's be with treat two,

doing that been vitro lot environment. experiments we've so setting hypoxic And a in in how immune the our of overcomes to see

see has cell to these successfully. impairments tumor solid to to So treat -- therapy overcome

I've solid presence cells that And patients the human we've cancer, prostate cells cells TME. solid that and converts into to So cells. these extreme cell that cells normal NK as preclinical and immunosuppressive lies what recently, immunoregulatory -- in in immune even memory-like shown INKmune healthy cancer, NK-resistant patients from most target targeting said, are carcinoma data cancer, breast the donors of tumors the NK cells. the resting with tumors from cells called that hypoxia and cancer nasopharyngeal shows company's ovarian from and cancer renal primes NK see we NK

blood resting comparing cells lines. kill all when patients the peripheral which normal NK immune healthy So from NK immune, tumor are or treatment of resistant demonstrated prime ability cells before cells with donors these enhanced or NK, cell to

invited was conference, Killer the Europe at enough be to Innate on present October to these data a fortunate So Summit XX. in I recent

such Therapies available video website of But field the the or immune novel a them of on of or of channel. it's consider therapies, supply. for regulatory videos understanding the agencies the is before company's type gene extensive they'll licensing that YouTube apparent the require the tab becoming the of FDA as commercial drugs of And mechanism cell in increasingly action company's these and that presentation under

field therapy in cell attempt and the the the different in this mechanism is a called in And gene no companies what's of are are understand we better science-driven all getting to heavily and field So action. BLA.

Now and between back to going we're upon very works, used early latest proteomics, explained Immune action lucky XXXX. the cells since because in INmune differences based INKmune-primed cells competitors. Bio, and the and the with cytokines data been NK and they data work how immune focused our publication of And we've our by delineate mechanism XXXXs, is metabolomics of genomics first our prime the on clearly from NK

you're if these video recent complex of presentation The and I you to watch very and some data, encourage go explains them. interested

trial activity. action, away And parallel the we adoptive outpatient Phase setting, INKmune So course, therapies. with an safety with patients patients associated expand our basis, about treatment which recent was planned so clinical on a that's I aim. increasing continue treat of of to regimen in is trial driving of have world the and complete days our treated a hospitalization X current and most complete cell patient Indeed, scenario. far our X-dose from with in obviously, received knowledge mechanism it's the our

outcome. the to treated and I so which identify of data shown all NK predict evidence clinical activation those Vivo, far in patients best As have said, analyzing cell we're biomarker

patient hospital with The XX occasional first and quality remains enjoying only is life treatment well treatment visits. MDS improved post are months of much

targeted patient bone a had with transformed the obviously, acute trial was disease The failure. from which leukemia, MDS, of the with second and mild marrow young lady

she transplants cell In X fact, (inaudible) received failure. marrow allogeneic stem and

relapsed that in treatment neutral months So her which is a from reduced earlier and a for after of we months we're hospital was indication she get home to pain, But transplant. in unexpectedly in recovery, after counts blood fourth cell with an treated Clinically, due allowed stabilized her. a allogeneic INmune. over she And she X scheduled and X having died quickly experienced INKmune hospitalized her load. been bone this discharge month sadly, such for had neutropenia, after to she tumor summer, and reduction

chemo-refractory patient at third chemotherapy, moment. oral the low-dose het a third is treated transplant and The has awaiting

in immune Our with transplant. disease chemotherapy, transplant how in July achieved evidence and back in showed emphasize XXXX. most awaiting she was treated her recent therapy in bone XXXX leukemia very are. second XX-year relapsed acute one severely level unrelated patient after After NK low function, patient, cell I further relapsed improved consolidation detectable enough She of with year. young and compassionately and treatment. an remission further she patients old marrow myeloid with well ill a a this as remains can't she who another MDS And again, after is these unrelated

the using whilst dose So lowest drug. in to we're the restricted immune of and the development at very early of being the moment

So all of lowest these patients the to of the XX cells. X dose have received

investigator, after improvement chief improvement Our to receiving.” even “all or treated looks the well-being all in said they've give fevers, performance were of fitness who subjective of and Definite chemotherapy resolution has appetite general enjoyed and X stabilized the able mood, status. low-dose from blood with parameters indeed and counts been in brakes improved recently, patients, trial clinical

So greatly. that us encourage

the of trial in Society American selected now few December. in furthermore, has And been for in Conference Hematology the at New weeks' a time Orleans Annual presentation

Finally, like in trial compassionate trial the the to cases enrolled be future. we've received widen X allow the inclusion the to approval in criteria to patients

product a to increased is of application second In on doing in an this submitted Friday. to company preparation presentation mine further. of trial to colleagues site third and the site of combination discussion Agency Greek the in now the the initiation process mechanism INKmune trial in action, trial recruitment the basic and opening The the manufacturing in and there in for the now put the tumor Xth is has RJ. complete, open XX-month XXXX. improvements into Athens before in next trial U.K. of of the an the the clinical upscaling and the indication the speed is new year. into delay trials to excellent new runs I'll for trial ongoing the back Medicines validation U.K. solid operations November pass for manufacturing of to company position the indications, that tumor the ready manufacturing we're at scheduled LAUREL the The present, also up has capitalization trials -- research for the the call in and I'm recruitment a the with end of solid in after company an in the Moreover, CGMP MDS of invested process

Thank you, Mark.

and calendars turns was months Phase advanced first an program, I of the Expo as with year, the company's fact, last with we couple oncology. our clinical Many As we have program passed that towards solid DN-TNF -- enter actually of the we events in patients in the with tumors. oncology forget trial

at the Breast presentations in in Immunotherapy X Cancer Cancer, the oncology is San Antonio SITC, the meetings ASH, We months. last of of will for weeks Society Society American of Symposium the the have X next occur all X Hematology year. which and

mentioned already resistance Antonio therapy on Breast HERX-positive breast presentations an Antonio use and San has ASH Symposia Symposium cancer of of to after ADC will The of the Breast market has with in are been as include breast SITC that very reduce news we combination each immunotherapy develop has provided MUCX closer recently, HERX-positive to get Cancer Mark More in the best details still the in doubled disease available half more medicines expressing the resistant Particularly tumors. but with cancer. these the on San and a therapy the be a even presentation. data of will event. DN-TNF presentations Cancer than patients today. each It size is lot. large

We at which the clinical end Alzheimer's CTAD, as month. is in attending the disease will you of be ending expect, to also, might trials

this Moss, I'd to like point, call David David? turn to the financial certain CFO, review to At over items. our

and provide the loss to I'll financial attributable upcoming million in September million 'XX. overview for totaled $X.X million approximately $X.X the comparable the quarter the development our for comparable results $X.X XX, session. RJ. approximately million quarter XX $X.X XXXX, September compared for for period million the September with approximately $X.X common 'XX. before ended compared compared ended stockholders XXXX. approximately million for in you, head a we XXth, Thank ended was our and with to in Research of XXXX, brief Q&A Net expense quarter General and approximately period $X.X to expense the period XX, comparable for was administrative milestones

company of our million. plan, operations fund XXXX, the operating As had XXXX. cash our equivalents Based of and cash have cash current we to believe September XXth, on approximately through $XX.X we sufficient

in As of number the burn point stock outstanding, I'd like our further shares that approximately the X budgeted we've because had had than the trials November delays of quarters. Xnd, been XXXX, has company U.S. same million last of XX.X the in the to common the out less because starting

of past, cash activity into -- for increased returned we've alternatively our as or and the lowered eligible because this budgeted rebates rise which we're help of more we've been Together, Australia, the the has we of reinvest runway dollar dollar, overall. Australian in doing the our manage Further, programs. costs anticipated our helped efficiently. of in developments us Australia the U.S. that the Further, clinical in the fall trial these

Now milestones. I'd like on move upcoming list to our and

remains attention review, the Australia currently to treatment Although our cause for FDA of provide with on trial the X-month expected but to slip Phase pending it for neuroinflammation in months date 'XX, of much Expo year. Top to reach target patients manufacturing disease time the II the is the will update the results Alzheimer's enrollment as order end we this tentatively continues an over whole of program coming enrolling if line late the hold lines on 'XX. continue into expect longer, We'll at in XXX.

II FDA Phase impairment. anticipate path review. X-month 'XX. Phase XPro depression. resolution continues, X.X we FDA late the treatment-resistant by plan partially right slip manufacturing of resolution ‘XX remains pending top of patients in we on unexpected XX-patient II the delays, will NIH a program FDA And to this our initiate of the the to funded grant any Bearing again, That's cognitive it mild trials results inquiry, remain upon million if into Upon for initiate hold having Additionally, with

Additional with high-risk open-label half Lowdell in potentially U.K. along more and Phase MDS/AML first as the and I the data of initiation earlier. sites mentioned of 'XX, Mark Greece, in INmune had the of

in study FDA. announced which second approval launch a the to we plan with solid Finally, tumor indication, INKmune upon a we

We in of half first XXXX. this to occur expect the

to turn to back like operator for and it At thank questions. your Donna? I'd to I'd attention. time this to point, the like for you poll

Instructions]. [Operator

Tom to Our coming today from first BTIG. is of Shrader question going be

At have you have you you to patients, I to of just question. -- worry from you too fraction enrolling and Australia? have have some any presumably, Australia. are a in many some want do Could you U.S. patients risk having of point, stop

for Thanks. Yes. CJ. No. really this, not I'll X take be a that risk will do reasons. I believe

to in II we the do But got not other after Biogen a that having speculated near anti-amyloid after is -- the II. actually future. place anticipate venues able more in I I Phase remember, out although no all is after that importantly, approved. trial. first this I over remember of we The that bruhaha Phase be longer approval the a believe lecanemab might get drugs. of

do We will trial. Phase have III a to

It only that includes United Japan. undoubtedly States and trial we one. and Hopefully, have will international both to do the Europe be an

that's do worry at all. reasonable So not question, but a I

things I are of increasing the issue aside, get And best to States, diversity is that the in an FDA place in think that's Australia. as that is on. the United an trials. focused the on just one is focused clinical obviously, And in we not diversity the

many or to at have that change then the the companies do very thought people boxes you really should that's talked the lecanemab of question, good on CDR worked well. You're in better a worked one But boxes be very well most of points. trial because seems co-primary have only focused think one readout the sum alternate end is have CDR I And the how about of did your surprises sum endpoints. in all? I of after a thinking so Does it

CJ?

Yes, Tom. I can take this. Thanks,

the study to an see endpoint, we actually on the recall and is you secondary a the effect CDR. powered So may CDR

don’t combination the we well. we’re to. if this the try fairly it to fairly well. not But And We to think the cognitive reinvent point, still cognitive CDR performs better to of So and endpoints for functional, wheel there are have going group. perform does your

I we to RJ the have a enough Phase So as the think not patients. do it’s the mentioned, – is exactly III is study. Phase to powered II study, and jury out know how registration study, that Again, still towards

really think we’re in a I So position. good

question B. Securities. next from coming Riley of Mayank is The Mamtani

AXX the Australia number study parameters. say And data a many at looking what and advanced, just how have did sets I you II as on study -- of So there? cohort, biomarkers data you're you know patients enrolled of components these the Phase then safety

As you get you do get just you open-label parameters the curious if into give a... into? what section, unblind can I'm

So trial -- the the Remember, yes, II so of let me is a Phase clarify couple blinded, randomized. of portion things.

that in be study I'll who let So on clinical But were who open-label is the trial different are get extension slip number. we've the patients a data months. The technical in patients be the end that months might what And portion. if top that to what patients actually, promising X of placebo, up talking term XPro of that's continues happens the what XX readout information if they if I up to no to is want on the guess, there CJ open-label when get they to continue has on about. before will are they you And mentioned, those are by it's the get for been unblinded that we'll is a all for And XXXX, XX be extension comment patients on for who much patients, FDA months. available totally crossed even may open-label want longer. CJ, different hold over line XPro to therapy.

Thanks, RJ.

terms blood point It be is will are at think thing. endpoints and I the the that Mayank, be similar the doing we look So out to in that -- clinical collecting data. are of will and of the MRI thing how going sort biomarkers to the

data. to me the doesn't If I big a clinical placebo we of think not there really tell they're It patients know on drug, know the is most a anything. relates open-label important am effect. thing it fan I cognitive absolutely as data,

biomarkers what But the Phase it value, data of So before that my I interesting. looks what in Phase will extension of same see, to limited we'll assuming study study. the biomarker way? that's be close performing is in that like is opinion. available data We of are the blinded the the the want II know open-label Part

the homogenous a that's see things Are in think and that matter metrics an and at. continuing here. that going difference. that got more white these group I are us the help we to And is expectation to to other And important some us. see got we've improvement of particular really We've we're we'll and looking a

not difference get think being I from it's in if in the those in from on XPro that to study versus is see interesting into what come that going trajectory. come there's to patients XPro on their the a being

or as answer don't enroll And course, have been time I to of not in how the moving be or the number know that we're that the by put they drug and value, data get will know going into all of in about what the they it I as not forward whether bucket. But clinical is. relates patients active duration and it of we placebo. of will study, think on mentioned, terms to development

about safety approval. that we database need it Does it's and about and long-term up but your -- So question? that safety to get safety I'm to -- it's that build talking of answer primarily, can will really absolutely not efficacy, is before we

how you now the Did are that. many Yes. in missed say study? I

enrollment numbers the planning halfway at said that that. we're update and So going do to we mark, we still are have to

So stay tuned.

And trying also quickly, do doses then in as had that to were of And kind able And the just Just earlier shelf you're the hold, under what if turnaround discussions for hand agency? that the how on comment understand that in the it. year getting and the on the of this with waiting times of you procedure manufacturing fall you program. life are they does oral? volume you the query. now on regulation to these Got submitted process question

Yes.

things. X So

goes It about XX-day -- a that's the XX-day inefficient. somewhere turnaround communication nature -- and just it is these to -- all, XX- the very is the of on beast. of First

the get campaigning a or no is because very we about that have there, concern out drug but think within efficient to drug the be I more subsequent campaign have we're or going a manufactured date, believe additional with There a will well of that We still of we current date, face-to-face running them we we batch process. almost is been drug of has only -- We out hope. original hard part not actually dating. video conference a as

So we're -- there's frustration assays that no these concern that we're is going exist. to run couple this just of didn't out a of drug. continued There over

the The manufactured the around causing first when the with us and past some go was drug in is now FDA. conversations

issue. through it. has the always David this. FDA will place, we're not technical just an by issue. This process says, in is we safety that As a It's This and is inefficient manufacturing a tracked get

I'm And sure then that. And Lowdell. you get just Understood. will through Dr. quickly for

ASH. were see what And first XXXX patient we you that make On to -- the patients what X give half color this first think I heard -- of you you have learn to population half to here? you open be And right may in readout? XXXX. you want XXXX the want presented on what of in you that determination just to look that label can in helpful from high-risk I I MDS/AML Like about data update guess,

Yes.

to test expected to efficacy. I not trial to is trial I regulatory test or in we think to to are safety design safety, show this a cancer remember a a where, we Phase perspective, from have

do big acts the have, population. that of one is patient biotech balancing choose this your you So how all companies

which will in trial patients to safety we see we've to said recruitment. trial build So we clinical throughout associated are always MDS rollout continue to identify believe going biomarker data use to try and benefit out on this as that's to our the we pay we And get data any and the to changes with trial find.

as But towards putting work. to had what constructive on allowing solid for solid our FDA And place in tumor. the move a very the ways in over dialogue to the with trial speed we're that's we're said, we recruitment. us I tumor parallel, very, put together And IND focusing up

So treated already January. data submitted LAUREL patients we trial will in obtained that have to the we’ve make our IND FDA the And possible. X the from

So without never gone FDA for we to those in trial data. have a tumor solid a could the

paid off X in So they’ve already just patients.

Obviously, we out the with January. intend But the tumor soon of more as filed for our have to it as time. IND solid pivot to schedule get time is

for delay In would it past experience have FDA’s will we in good on it my But people desk January, were Christmas fact, ready dropping Christmas. because news. in the isn’t

very enormously the will the our first turn the moment. solid trial or end IND trial with quite of in enroll me a excites patients to record the So next at we by in time And submission aim really our inn the first in have around tumor first in QX and U.S. early in QX the U.S. year. that’s what

will up perspective, a we as data. drug them in and we the I’m will patients the a have MDS to I trial. – you’ve on increasingly list using following we MDS trial patients implied, more very perspective, we that be as development those from But enrolled enroll haven’t disappointed say,

patients the present side, data being trial, the at not allowed enrolled plus wouldn’t have been American we the hematology all the present able to to that you’re because in had On in conference. trial site

the So with world the patients does data that in fact December. hematologists compassionate share the around opportunity we’ve to us to use give present those got

yes, I your So answered hope question. that

question [Operator Tailwinds Instructions]. from Daniel coming is Carlson Research. next of The

to how the of in patients done there. patients you well are wondering access do get in go regarding out drug? since of special this in I'm feedback off expect give have Australia CJ, For expect it terms being any And just you terms of you us what data. things being sounds like And scheme, where received Can the to with this? on the

Thanks, Dan.

it. out cut you gist a bit, of I I but think got I little think the

efficacious we is, what believe that Phase is dose. the to really it One that really the in have X an reinforce bring the were I does do think there's few reasons. what we study we So patients I reason is received the up consider drug going to

speaks intents and access the well. drug, all think, to For demand purposes, I continued very

there's can we it to a together much what big get protocol clinical for a it, As going anecdotal without that's expense pretty we data. regulatory can hurdles. out of all quite that's the putting through And relates and not full a

But do is the here it do we to we as we safety. from get commentary relates information And there. what and get get a can clinician

share Now not whether those. or can we that

that We And haven't ability in it's patients they're access remain safe that we provide -- the our one the don't longer maybe trials. that to our the database again, think assume some the really say I of But in and the current detail. to -- drug, we to from get have on would it. fit build discussed I benefit safety patients seeing

that point to that So track is thing, I these RJ? on right we're And think are the we're same here. which at. the things looking I'll

clinical an just trials, my that's look X clinical or background, at this teams haven't intriguing to it's off patient I'd I find what want But oncology patients I the interesting drug. not drug. that off question, care clinical doing like Yes, patient is trial. be well, if don't is, taken end Their to of have in even to sides like that from adamant add, And position here. the transplant take don't Dan. the your remember, the very are I the with seen I that the look, I

if the has and clinical the the getting treating So this process And of thrilled we're happen. mechanisms the fine been it's benefit, a you that. the and And the with of all patients. CJ make in to patients end out they're in putting all teams or is we're At day, figure think about in how mechanisms. the

removed having a to product from aren't patients the benefit. if they seem So be

the with just then for you you. but patients them in the I'm on also not factor thinking drugs over now. where the terms X in no, to trial that curious having running working FDA, Got safety, regard for Australia say with of and into right? it's And it's months elsewhere their to if easy Does

these listen. them as we've about Well, can And they imagine, patients. you told think I

death. these technical us problems -- don't we will if over patients I think have beating before to completely head them think long comes they're not to it that, in it enough take tone they're well solve But getting more that. I hope the -- it enough with getting

You approval ADCOM was of that -- they a in the that could instance fact second Amylyx argue, the result got Canada. for in or drug ALS the really the approved

their completely but is they not them ways change they think tone the carefully. I have deaf, and So FDA

Can I RJ? real quick, this on comment

Yes, please do.

think the remember, this Dan, So I is real blinded issue is, study. a

break So blind causing any safety with to that I'm to trial. to how the data. not problem you sure do that, that without a we need the And data would we big bring sharing

take deal with that -- As RJ other we've issue. think said, I the got can to avenues we're

solid that And one is question. those? tumor, sense. for going wondering be cancer Yes, last makes what just I'm target the then the to

we're with we've to say going you trial to large globally on work issue the tumor unmet of like the I'd has need States, got be in It's to the a United that, big that's a run want to a in very is such who our which the and until -- certainly but that able large to tell why filed IND. clinicians us. we've a number states want

it's opportunity large our a one to I'm work population first reason excited patient because need. in significant very why So so it's with unmet another a

Yes. to sure we We're not making sensitive very make trying give here, are they evasive Dan. -- that just promises, accurate. are that It's to we when be

news. cautious provide ways, speak. a then in have So about than in rather, we're to past some being And providing stale news, so we I'd little progressive news more the

lot appreciate the your fine. That’s a it’s faster enrolment the and excited hopefully, in And it, U.S. to work. good partners that about be are will good hear

over Thank you. time, I'd Dr. like to the this back comments. closing turn Tesi for floor At to

we therapeutic going think and know if us not future. this I go expertise X/X to appropriate, well but what it to is be call I the or where silo win think here standard well. is we've I the function. individual brought quarterly our have Please think did got new on is of really to speaking phone. for you So But more literally the company real not let in you've within the got of this -- company the format the each

INmune participation. company. complicated I So is anyway, Bio your a appreciate

They continue CNS many promise making interesting. are that we can a will innovative to oncology. will biologically programs. we with we forward, you and and We in the And have progress the are promising making both in I frustrations lives. difference are move FDA, and and Despite both patients'

nice very evening. much, So have a and thank with that, you

you for gentlemen, thank concludes and This participation. your event. today's Ladies

disconnect the time, lines of your rest day. this at webcast may You the your and walk-off enjoy and